VREX · Varex Imaging Corp
$18.50
+0.01 (+0.05%)
At close · Aug 21
Market Cap
$778.43M
Shares
42.10M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$18.49
Open$18.47
Day$18.45–18.50
52W close$9.32–18.58
Avg vol 30d1.1M
Short int1.2M · 2.9% float · 3.9d
Short vol35%
Last earningsAug 10, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 11 wks
FQ4-26 quarter ends
~Oct 2, 2026
Est
filed Aug 10, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+55%
above
Price vs 50-day avg
+51%
above
RSI (14)
90
overbought
MACD trend
Positive
52-week position
99%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+72%
trailing
6-month return
+40%
trailing
YTD return
+59%
this year
Relative strength
+29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $12 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.93% of float · ▲ +2.2% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
185 holders — mid 3-yr range
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
−9%
Y/Y
Gross margin
36%
expanding
EPS growth
−42%
Y/Y
Free cash flow
$18.8M
Valuation
P/E 35.6
rich
Balance sheet
$222.5M
net debt
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
2.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
second half of fiscal 2026
Revenue
up to 3%
full fiscal year 2026
Full fiscal year 2026 revenue
$860M – $880M
Non-GAAP EPS
Non-GAAP
$0.80 – $1.00
Prior guidance
period ended
· from the 8-K filed May 7, 2026
Revenues
· third quarter of fiscal year 2026
$210M – $225M
Non-GAAP net earnings per diluted share
· third quarter of fiscal year 2026
$0.15 – $0.30
Guided vs delivered
· last 5 settled
Revenues
first quarter of fiscal year 2026
guided $200M – $215M
$209.6M
In line
Revenues
fourth quarter of fiscal year 2025
guided $210M – $230M
$228.9M
In line
Revenues
second quarter of fiscal 2024
guided $195M – $215M
$206.2M
In line
Revenues are expected between $180 million and $200 million
first quarter of fiscal 2024
guided $180M – $200M
$190M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+55%
Bullish
Price vs 50-day avg
+51%
Bullish
RSI (14)
90
Bearish
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
Golden cross
50d $12 › 200d $12 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.93% of float · ▲ +2.2% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
185 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $9
Now $18 · 99%
Range high $19
vs 200-day avg +55%
vs 50-day avg +51%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $88.2M | Nine Months Ended July 3, 2026 | — |
| Non-GAAP diluted net income per share non-GAAP | $0.71 | Nine Months Ended July 3, 2026 | — |
| Non-GAAP gross margin % non-GAAP | 34.7% | Nine Months Ended July 3, 2026 | — |
| Non-GAAP income before taxes non-GAAP | $38M | Nine Months Ended July 3, 2026 | — |
| Non-GAAP income tax expense non-GAAP | $7.5M | Nine Months Ended July 3, 2026 | — |
| Non-GAAP net income non-GAAP | $30.1M | Nine Months Ended July 3, 2026 | — |
| Non-GAAP operating income non-GAAP | $62.7M | Nine Months Ended July 3, 2026 | — |
| Non-GAAP operating margin % non-GAAP | 9.9% | Nine Months Ended July 3, 2026 | — |
| Cash outflows from operations | $2M | Q2 FY2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VREX
this stock
Varex Imaging Corp
|
$778.43M | +58.7% | -9.2% | 35.6 | 2.9% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$120.49B | -3.9% | +8.4% | 25.2 | 1.4% |
|
BSX
Boston Scientific Corp
|
$71.55B | -48.2% | +12.5% | 20.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VREX | -0.1% | +72.5% | +40.4% | +65.2% | +58.7% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +1.9% | +69.2% | +29.2% | +63.2% | +46.9% |